Literature DB >> 15381288

Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment.

G De Foubert1, S L Carney, C S Robinson, E J Destexhe, R Tomlinson, C A Hicks, T K Murray, J P Gaillard, C Deville, V Xhenseval, C E Thomas, M J O'Neill, T S C Zetterström.   

Abstract

Recent studies indicate that brain-derived neurotrophic factor (BDNF) may be implicated in the clinical action of antidepressant drugs. Repeated (2-3 weeks) administration of antidepressant drugs increases BDNF gene expression. The onset of this response as well as concomitant effects on the corresponding BDNF protein is however, unclear. The present study investigated the effects of acute and chronic administration of the selective serotonin reuptake inhibitor, fluoxetine (10mg/kg p.o.), upon regional rat brain levels of BDNF mRNA and protein expression. To improve the clinical significance of the study, fluoxetine was administered orally and mRNA and protein levels were determined ex vivo using the techniques of in situ hybridisation histochemistry and immunocytochemistry respectively. Direct measurement of BDNF protein was also carried out using enzyme-linked immunosorbent assay (ELISA). Four days of once daily oral administration of fluoxetine induced decreases in BDNF mRNA (hippocampus, medial habenular and paraventricular thalamic nuclei). Whilst 7 days of treatment showed a non-significant increase in BDNF mRNA, there were marked and region-specific increases following 14 days of treatment. BDNF protein levels remained unaltered until 21 days of fluoxetine treatment, when the numbers of BDNF immunoreactive cells were increased, reaching significance in the pyramidal cell layer of CA1 and CA3 regions of Ammon's horn (CA1 and CA3) but not in the other sub-regions of the hippocampus. Indicative of the highly regional change within the hippocampus, the ELISA method failed to demonstrate significant up-regulation at 21 days, measuring levels of BDNF protein in the whole hippocampus. In contrast to the detected time dependent and biphasic response of the BDNF gene, activity-regulated, cytoskeletal-associated protein (Arc) mRNA showed a gradual increase during the 14-day course of treatment. The results presented here show that BDNF is expressed differentially depending on length of fluoxetine administration, which could contribute in explaining the slow onset of antidepressant activity observed with selective serotonin reuptake inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381288     DOI: 10.1016/j.neuroscience.2004.06.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  74 in total

1.  Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors.

Authors:  M S García-Gutiérrez; J M Pérez-Ortiz; A Gutiérrez-Adán; J Manzanares
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Targeting the hippocampal mossy fiber synapse for the treatment of psychiatric disorders.

Authors:  Katsunori Kobayashi
Journal:  Mol Neurobiol       Date:  2009-01-08       Impact factor: 5.590

3.  Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.

Authors:  Mary M Torregrossa; Emily M Jutkiewicz; Henry I Mosberg; Gianfranco Balboni; Stanley J Watson; James H Woods
Journal:  Brain Res       Date:  2005-12-20       Impact factor: 3.252

4.  Astrocytic GABAB Receptors in Mouse Hippocampus Control Responses to Behavioral Challenges through Astrocytic BDNF.

Authors:  Ji-Hong Liu; Ze-Lin Li; Yi-Si Liu; Huai-De Chu; Neng-Yuan Hu; Ding-Yu Wu; Lang Huang; Shu-Ji Li; Xiao-Wen Li; Jian-Ming Yang; Tian-Ming Gao
Journal:  Neurosci Bull       Date:  2020-03-12       Impact factor: 5.203

5.  Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism.

Authors:  Katrina L Paumier; Caryl E Sortwell; Lalitha Madhavan; Brian Terpstra; Stephanie L Celano; Joshua J Green; Nastassja M Imus; Nathan Marckini; Brian Daley; Kathy Steece-Collier; Timothy J Collier
Journal:  Neuropsychopharmacology       Date:  2014-09-30       Impact factor: 7.853

6.  High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression.

Authors:  Thorsten Mikoteit; Johannes Beck; Anne Eckert; Ulrich Hemmeter; Serge Brand; Roland Bischof; Edith Holsboer-Trachsler; Alexandra Delini-Stula
Journal:  Psychopharmacology (Berl)       Date:  2014-02-23       Impact factor: 4.530

7.  Sleep disturbance as detected by actigraphy in pre-pubertal juvenile monkeys receiving therapeutic doses of fluoxetine.

Authors:  Mari S Golub; Casey E Hogrefe
Journal:  Neurotoxicol Teratol       Date:  2016-03-05       Impact factor: 3.763

8.  Interaction between the BDNF gene Val/66/Met polymorphism and morning cortisol levels as a predictor of depression in adult women.

Authors:  J Herbert; M Ban; G W Brown; T O Harris; A Ogilvie; R Uher; T K J Craig
Journal:  Br J Psychiatry       Date:  2012-07-26       Impact factor: 9.319

9.  The roles of BDNF, pCREB and Wnt3a in the latent period preceding activation of progenitor cell mitosis in the adult dentate gyrus by fluoxetine.

Authors:  Scarlett B Pinnock; Alastair M Blake; Nicola J Platt; Joe Herbert
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  Brain-derived neurotrophic factor: role in depression and suicide.

Authors:  Yogesh Dwivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.